L3 HAS NO ANSWERS
L3 STR



VAR G1=H/C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

=> d his l5

(FILE 'REGISTRY' ENTERED AT 12:48:27 ON 13 APR 2009)
L5 32 S L3 FUL

=> d his l6

(FILE 'CAPLUS' ENTERED AT 12:51:11 ON 13 APR 2009)
L6 4 S L5

=> d bib abs hitstr 1-4

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:612282 CAPLUS
DN 143:133095
TI Preparation of amidino derivatives as cysteine protease inhibitors
IN Graupe, Michael; Lau, Agnes J.; Li, Jiayao; Link, John O.; Mossman, Craig J.; Woo, Soon H.; Zipfel, Sheila M.
PA Axys Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063742	A2	20050714	WO 2004-US43451	20041222
	WO 2005063742	A3	20050818		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	EP 1697355	A2	20060906	EP 2004-815518	20041222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	JP 2007516295	T	20070621	JP 2006-547413	20041222
	US 20070105892	A1	20070510	US 2007-583629	20070110
PRAI	US 2003-532243P	P	20031223		
	WO 2004-US43451	W	20041222		

OS CASREACT 143:133095; MARPAT 143:133095

GI



I



II

AB Title compds. I [R1 = benzoxazol-2-yl, oxazolo-[4.5-b]-pyridin-2-yl, 2-ethyl-[1.3.4]-oxadizol-5-yl, etc.; R2 = Et, n-propyl; R3 = cyclohexylmethyl, cyclopentylmethyl, 1-methylcyclohexylmethyl, etc.; R4 = Me, Ph, isopropylamine, etc.; R5 = methylsulfonyl, ethoxycarbonyl, pyridin-3-ylsulfonyl, etc.; or R4 and R5 together = 1,1-dioxobenzo[d]isothiazol-3-yl or 1,1-dioxo-1,4-dihydro-λ6-benzo[1.2.4]thiadiazin-3-yl] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of cysteine proteases. Thus, e.g., II was prepared by subsequent couplings of 2(S)-amino-3-cyclopentyl-3-methylpropionic acid hydrobromide with 3-chlorobenzo[d]isothiazole-1,1-dioxide and 2(S)-amino-(3-ethyl-[1.2.4]-oxadiazol-5-yl)butan-1-ol followed by oxidation with Dess-Martin periodinane. The activity of I was evaluated using chromogenic enzyme assays following the inhibition spectrophotometrically (at λ = 460 nm) and it was revealed that compds. of the invention displayed inhibitory activity against cathepsin K, L, S and F (no data). I as inhibitor of cysteine proteases should prove useful in the treatment of psoriasis and Grave's exophthalmos. Pharmaceutical compns. comprising I are disclosed.

IT 858102-23-5P 858102-24-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidino derivs. as inhibitors of cysteine proteases)

RN 858102-23-5 CAPLUS

CN Cyclohexanepropanamide, 1-methyl-N-[(1S)-1-[(3-phenyl-1,2,4-oxadiazol-5-yl)carbonyl]propyl]-α-[[1-[(3-pyridinylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858102-24-6 CAPLUS

CN Propanamide, N-[(1S)-1-(2-benzoxazolylcarbonyl)propyl]-3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-2-[[1-[(3-pyridinylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:1074184 CAPLUS

DN 142:56668

TI Preparation of amidino compounds as cysteine protease inhibitors

IN Patterson, John W.

PA Axys Pharmaceuticals, USA

SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004108661	A1	20041216	WO 2004-US17654	20040604
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2526694	A1	20041216	CA 2004-2526694	20040604
	JP 2006526657	T	20061124	JP 2006-515175	20040604
	EP 1761485	A1	20070314	EP 2004-776274	20040604
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
	US 20060264464	A1	20061123	US 2006-559405	20060626
PRAI	US 2003-475612P	P	20030604		
	WO 2004-US17654	W	20040604		

OS MARPAT 142:56668

AB The invention is directed to compds. and pharmaceutical compns. that are inhibitors of cysteine proteases, in particular cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. Amidines of formulas R4N:CR3NR2CR1R1aCONH-E and R4R4aNCR3:NCR1R1aCONH-E [E is -C(R5)(R6)X1 or -C(R5a)(R6a)CN, where X1 is CHO, -C(R7)(R8)CF3, -C(R7)(R8)CF2CF2R9, -C(R7)(R8)R10, -CH:CHSO2R10, etc.; R5 and R5a are independently H or alkyl; R6 and R6a are independently H, alkyl, haloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl,heteroaryl, etc.; C(R5)(R6) or C(R5a)(R6a) may form rings; R7 is H or alkyl; R8 is OH; or R7 and R8 form oxo; R9 is H, halo, alkyl, aralkyl or heteroaralkyl; R10 is alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, or heterocyclylalkyl in which the aromatic or alicyclic ring is optionally substituted; R1, R2 are H or alkyl; R1a is H, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, etc.; or CR1R1a is (un)substituted (hetero)cycloalkylene; R3 is H, alkyl, haloalkyl, cycloalkyl, aryl, aralkyl, heteroaryl, amino, etc.; R4 is (un)substituted phenyl- or naphthylsulfonyl; R4a is H, alkyl, halo, haloalkyl, hydroxyalkyl, alkoxy,hydroxy, aryl, etc.] or their pharmaceutically-acceptable salts are claimed. Thus, N-[(phenylsulfonylimino)methyl]cyclohexylalanine cyanomethylamide was prepared via reactions of cyclohexylalanine Me ester hydrochloride, Et benzenesulfonylformimidate, and aminoacetonitrile hydrochloride. The biol. examples describe cathepsin assays and pharmaceutical formulations containing compds. of the invention.

IT 808754-71-4P 808754-82-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amidino compds. as cysteine protease inhibitors)

RN 808754-71-4 CAPLUS

CN Propanamide, N-(cyanomethyl)-3-[[[2-(difluoromethoxy)phenyl]methyl]thio]-2-[[[(phenylsulfonyl)amino]methylene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-82-7 CAPLUS
CN Cyclopentanepropanamide, N-(4-cyanotetrahydro-2H-thiopyran-4-yl)-1-methyl-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 808754-67-8P 808754-68-9P 808754-69-0P
808754-70-3P 808754-72-5P 808754-73-6P
808754-74-7P 808754-75-8P 808754-76-9P
808754-77-0P 808754-78-1P 808754-79-2P
808754-80-5P 808754-81-6P 808754-83-8P
808754-84-9P 808754-86-1P 808754-87-2P
808754-88-3P 808754-89-4P 808754-90-7P
808754-92-9P 808754-93-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidino compds. as cysteine protease inhibitors)
RN 808754-67-8 CAPLUS
CN Cyclohexanepropanamide, N-(cyanomethyl)-α-[[[(phenylsulfonyl)amino]methylene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-68-9 CAPLUS
CN Cyclohexanepropanamide, N-(cyanomethyl)-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-69-0 CAPLUS
CN Cyclohexanepropanamide, N-(1-cyanocyclopropyl)-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-70-3 CAPLUS
CN Cyclohexanepropanamide, N-(1-cyanocyclopropyl)-α-[[[(phenylsulfonyl)amino]methylene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-72-5 CAPLUS
CN Propanamide, N-(cyanomethyl)-3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-2-[[[(phenylsulfonyl)amino]methylene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-73-6 CAPLUS
CN Cyclohexanepropanamide, N-(4-cyanotetrahydro-2H-thiopyran-4-yl)-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-74-7 CAPLUS
CN Cyclohexanepropanamide, N-(4-cyanotetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-75-8 CAPLUS
CN Propanamide, N-(cyanomethyl)-3-[[[2-(difluoromethoxy)phenyl]methyl]thio]-2-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-76-9 CAPLUS
CN Propanamide, N-(cyanomethyl)-3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-2-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-77-0 CAPLUS
CN Propanamide, N-(cyanomethyl)-3-[(phenylmethyl)sulfonyl]-2-[[[(phenylsulfonyl)amino]methylene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-78-1 CAPLUS
CN Propanamide, N-(4-cyanotetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-2-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-79-2 CAPLUS
CN Cyclopentanepropanamide, N-(cyanomethyl)-1-methyl-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-80-5 CAPLUS
CN Propanamide, N-(cyanomethyl)-3-[(phenylmethyl)thio]-2-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-81-6 CAPLUS
CN Propanamide, N-(cyanomethyl)-3-[(phenylmethyl)sulfonyl]-2-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-83-8 CAPLUS
CN Cyclopentanepropanamide, N-(4-cyanotetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-1-methyl-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-84-9 CAPLUS
CN Cyclohexanepropanamide, N-(1-cyanocyclopropyl)-1-methyl-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-86-1 CAPLUS
CN Cyclohexanepropanamide, N-[(1S)-1-(2-benzoxazolylcarbonyl)propyl]-α-[[[(phenylsulfonyl)amino]methylene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-87-2 CAPLUS
CN Propanamide, N-[(1S)-1-(2-benzoxazolylcarbonyl)propyl]-3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-2-[[[(phenylsulfonyl)amino]methylene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-88-3 CAPLUS
CN Propanamide, N-[(1S)-1-(2-benzoxazolylcarbonyl)propyl]-3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-2-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-89-4 CAPLUS
CN 2-Thiazolepropanamide, N-[(1S)-1-(2-benzoxazolylcarbonyl)propyl]-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-90-7 CAPLUS
CN Cyclopentanepropanamide, N-[(1S)-1-(2-benzoxazolylcarbonyl)propyl]-1-methyl-α-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-92-9 CAPLUS
CN Propanamide, 3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-N-[(1S)-1-[(5-ethyl-1,3,4-oxadiazol-2-yl)carbonyl]propyl]-2-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808754-93-0 CAPLUS
CN Propanamide, 3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-N-[(1S)-1-[(3-phenyl-1,2,4-oxadiazol-5-yl)carbonyl]propyl]-2-[[1-[(phenylsulfonyl)amino]ethylidene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 808755-30-8P 808755-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidino compds. as cysteine protease inhibitors)
RN 808755-30-8 CAPLUS
CN Propanamide, N-[(1S)-1-(2-benzoxazolylhydroxymethyl)propyl]-3-[[[2-(difluoromethoxy)phenyl]methyl]thio]-2-[[[(phenylsulfonyl)amino]methylene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808755-32-0 CAPLUS
CN Propanamide, N-[(1S)-1-(2-benzoxazolylhydroxymethyl)propyl]-3-[[[2-(difluoromethoxy)phenyl]methyl]sulfonyl]-2-[[[(phenylsulfonyl)amino]methylene]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1976:180201 CAPLUS
DN 84:180201
OREF 84:29207a,29210a
TI Penicillanic acid derivatives
IN Yamada, Hiroshi; Okano, Shigeru; Komatsu, Toshiaki; Katsura, Toyozo; Eda, Yasuko
PA Sumitomo Chemical Co., Ltd., Japan
SO Jpn. Tokkyo Koho, 4 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 50020079	B	19750711	JP 1970-118343	19701223
PRAI JP 1970-118343	A	19701223		

GI



I, R=H
II, R=CH:NSO2R1

AB Aminobenzylpenicillins I and their salts were treated with R2CH:NSO2R1 (II; R2 = alkoxy; R1 = aryl, pyridyl) to give II, and their salts. Thus, 0.5 g D-α-aminobenzylpenicillin Na salt, 0.355 g II (R1 = Ph, R2 = EtO) and EtOH was mixed at -15° and stirred 24 hr to give 0.53 g II (R1 = Ph) Na salt. Similarly prepared were II (R1 = 2-pyridyl, 4-AcNHC6H4). The min. inhibitory concentration of II against Staphylococcus aureus and Escherichia coli were 0.1-0.78 γ/cc, and 25-100 γ/cc, resp.
IT 56103-69-6P 56103-70-9P 59229-33-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 56103-69-6 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6-[[phenyl[[[(phenylsulfonyl)amino]methylene]amino]acetyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 56103-70-9 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6-[[phenyl[[[(2-pyridinylsulfonyl)amino]methylene]amino]acetyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 59229-33-3 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
6-[[[[[[[4-(acetylamino)phenyl]sulfonyl]amino]methylene]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2α,5α,6β(S*)]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1975:428219 CAPLUS

DN 83:28219
OREF 83:4521a,4524a
TI Penicillanic acid derivatives
IN Yamada, Hirotada; Okano, Shigeru; Komatsu, Toshiaki; Katsura, Toyozo; Eda, Yasuko
PA Sumitomo Chemical Co., Ltd.
SO Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 50002995	B	19750130	JP 1970-129957	19701228
PRAI JP 1970-129957		19701228		

GI For diagram(s), see printed CA Issue.
AB Penicillanic acids I (R = Ph, pyridyl) or their salts were prepared by treating HO2CCHPhNHCH:NSO2R or their reactive derivs. with 6-aminopenicillanic acid (II). I are bactericides. Thus, 0.54 g ClCO2Et was added to 1.7 g Na D-α-(N-phenylsulfonylformamidino)phenylacetate in CH2Cl2 at -10°, the mixture stirred 50 min, a suspension of 1.08 g II and 1.01 g Et3N in CH2Cl2 added, and the whole stirred 2 hr at 0° and 2 hr at room temperature to give 0.5 g I (R = Ph) (III). Min. growth inhibition concns. of III against Staphylococcus aureus and Escherichia coli were 0.2 and 25 γ/ml, resp. I (R = 2-pyridyl) was also prepared
IT 56103-69-6P 56103-70-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 56103-69-6 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[phenyl[[[(phenylsulfonyl)amino]methylene]amino]acetyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 56103-70-9 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[phenyl[[[(2-pyridinylsulfonyl)amino]methylene]amino]acetyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


O
O
Ph
H
H
Me
N
S
N
N
H
R
N
R
R
S
Me
O
N
S
O
CO2H